The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

about

Serotonergic targets for the treatment of L-DOPA-induced dyskinesia.Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.

P2860

Q48300577-1D74D13D-5672-4547-AACC-8A4438BE0BE2 Q49788107-F0CAED0C-C2E3-4430-AEF3-3F3B04C26123

P2860

The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

Item

http://www.wikidata.org/entity/Q53542537

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@en

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@nl

type

Item

label

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@en

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@nl

prefLabel

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@en

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@nl

P1476

The effect of mirtazapine on d ...... in the parkinsonian marmoset.

@en

P2093

Adjia Hamadjida

http://www.w3.org/2001/XMLSchema#string

Cynthia Kwan

http://www.w3.org/2001/XMLSchema#string

Imane Frouni

http://www.w3.org/2001/XMLSchema#string

Jim C Gourdon

http://www.w3.org/2001/XMLSchema#string

Lamia Sid-Otmane

http://www.w3.org/2001/XMLSchema#string

Mery-Jane Harraka

http://www.w3.org/2001/XMLSchema#string

Nicolas Veyres

http://www.w3.org/2001/XMLSchema#string

Philippe Huot

http://www.w3.org/2001/XMLSchema#string

Stephen G Nuara

http://www.w3.org/2001/XMLSchema#string

P2860

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

Parkinson disease psychosis: Update

The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.

Mirtazapine improves visual hallucinations in Parkinson's disease: a case report.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset.

Pharmacokinetics of mirtazapine and its main metabolites after single intravenous and oral administrations in rats at two dose rates.

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.

P2888

s00213-017-4530-z

P304

905-911

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-017-4530-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

234

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28130646

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

dopamine

dyskinesia

The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

about

P2860

P2860

The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P921